3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Thoracic
1
Plasma cell
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
9
Leukemia, Lymphocytic, Chronic, B-Cell
6
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Waldenstrom Macroglobulinemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Sezary Syndrome
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Burkitt Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Immunoblastic Lymphadenopathy
2
Thrombocytosis
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Interventions
Cyclophosphamide
6
fludarabine
4
Magnetic Resonance Spectroscopy
3
Flow Cytometry
3
trametinib
2
pembrolizumab
2
liposomal doxorubicin
2
dabrafenib
2
aldesleukin
2
Specimen Handling
2
Methylprednisolone
2
Immunologic Techniques
2
Gemcitabine
2
Dexamethasone
2
Biopsy
2
Azacitidine
2
Alemtuzumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sargramostim
1
saracatinib
1
sapanisertib
1
ruxolitinib
1
rucaparib
1
resiquimod
1
relatlimab
1
poly ICLC
1
pertuzumab
1
palbociclib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Everolimus
×
Plasma cell
×
Clear all
NCT02407509
2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1
Completed
104 enrolled